Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Our findings underscore the formidable challenge posed by PUC, emphasizing its limited response to current therapies. Despite higher pT0 rates with NAC, the OS benefit remains inconclusive, highlighting the need for more effective treatments.
Authors
- Adebowale Adeniran (ORCID: https://orcid.org/0000-0001-9820-632X)
- Michael Jalfon (ORCID: https://orcid.org/0000-0001-7351-3235)
- Victoria H. Kong (ORCID: https://orcid.org/0000-0002-2304-6146)
- Peter A. Humphrey (ORCID: https://orcid.org/0009-0006-9958-9717)
- Fady Ghali (ORCID: https://orcid.org/0000-0001-7417-1599)
- Jonathan Lawrence Wright (ORCID: https://orcid.org/0000-0002-8447-8209)
- Syed N. Rahman (ORCID: https://orcid.org/0000-0002-2646-6250)
- Joseph Kim (ORCID: https://orcid.org/0000-0002-6017-6871)
- Darryl T. Martin (ORCID: https://orcid.org/0009-0007-9931-6273)
- David Hesse
Institutions
- University of Washington (US)
- Yale University (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-01
- DOI
- https://doi.org/10.3390/cancers16173050
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15